Cerity Partners’s TriSalus Life Sciences TLSI Stock Holding History

Cerity Partners’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.3M	Buy	1,603,538 +816,266	+104%	+$3.24M	0.01%	919
2026 Q1	$3.15M	Buy	+787,272	New	+$3.85M	﹤0.01%	1235

Other funds holding TLSI

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WPC

White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Cerity Partners's TLSI Position: Q2 2026 in Review

Cerity Partners increased its TriSalus Life Sciences (TLSI) stake by 104% in Q2 2026, buying an estimated $3.24M and bringing the position to 1,603,538 shares worth $7.3M. The position accounts for 0.01% of the portfolio, ranked #919.

Cerity Partners first reported a position in TLSI in Q1 2026 and has held it in 2 quarters since. 79 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

Cerity Partners held 1,603,538 shares of TriSalus Life Sciences worth $7.3M as of Q2 2026.
Cerity Partners bought 816,266 TriSalus Life Sciences shares in Q2 2026, an estimated $3.24M.
TriSalus Life Sciences made up 0.01% of Cerity Partners's portfolio in Q2 2026, its #919 holding.
Cerity Partners first reported a position in TriSalus Life Sciences in Q1 2026 and has held it in 2 quarters since.
79 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.